Blog
PUBLICATION ALERT: AURORA Trial Published: Key Step Toward Expanded Use of Cardiac PET
- By: admin
- On: 10/11/2023 12:28:16
- In: Membership
The results of the AURORA (International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]) trial were published Oct. 9, in the Journal of the American College of Cardiology. The authors, led by Jamshid Maddahi, MD, FASNC, reported that PET imaging with flurpiridaz significantly exceeded prespecified threshold criteria for detection of CAD and was superior to Tc-labeled SPECT myocardial perfusion imaging for detection of CAD in the overall population and in women and obese patients.
Publication of the AURORA trial is an important step toward FDA approval of flurpiridaz, which has a longer half-life than currently available radiopharmaceuticals. This advantage would allow unit dosing and exercise testing as discussed in the accompanying editorial by Jamieson M. Bourque, MD, MHS, FASNC. As Dr. Bourque details, the newly published findings are "lighting the way to an exciting new era in cardiac imaging."
Consider the Big Picture
Undoubtedly, publication of the AURORA trial is a milestone in nuclear cardiology. Pause for a moment to also consider this occasion in the context of the many advances occurring in nuclear cardiology. In addition to having new radiopharmaceuticals on our horizon, nuclear cardiology is thriving due to innovations in –- Amyloid, infection, and inflammation imaging;
- Hardware and software enhancements; and
- Hybrid and PET imaging, myocardial blood flow assessment, and artificial intelligence.
Many more advances in nuclear cardiology are coming. ASNC is committed to keeping members current and providing context about what new developments mean for cardiac imagers and their labs. To ensure you are always up to date, RENEW YOUR ASNC MEMBERSHIP NOW, or JOIN ASNC TODAY.
Mouaz H. Al-Mallah, MD, MSc, MASNC
ASNC President